Last reviewed · How we verify
NCT06108089
Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment
trial testing [18F]MISO-PET/CT in Head and Neck Cancer in 20 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | University of Utah |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 28 June 2024 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- [18F]MISO-PET/CT
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Hypoxia — all drugs for Hypoxia →
- Magnetic Resonance Imaging — all drugs for Magnetic Resonance Imaging →
- Cancer Neck — all drugs for Cancer Neck →
Sponsor
University of Utah
Who can join
18 and older, any sex, with Head and Neck Cancer or Hypoxia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tumor hypoxia is one of the physiological factors for treatment resistance and likely contributes to poor overall survival among patients with head and neck cancer (HNC). Identifying hypoxic features of HNC may allow the personalizing treatment plan. The investigators propose multiparametric Hypoxia MR (HMR) imaging using diffusion, perfusion, and oxygenation as non-invasive, in-vivo imaging components of a hypoxia phenotype. Assessing the hypoxia phenotypes' expression will be critically important for characterizing and predicting CRT response among patients with advanced HNC. A prospective cohort study will be conducted used multiparametric MR (MPMR) imaging correlated with treatment response assessed by 3 months fluorodeoxyglucose-positron emission tomography (FDG-PET). The image analysis approach will be developed to incorporate FDG-PET and quantitative MRI characteristics of tumor (ADC, oxygen-enhanced T1 and T2\* maps, and volume transfer constant (Ktrans) to facilitate 3D visualization of multiparametric information. This proposed study's overarching goal is to develop and validate multiparametric HMR imaging using 18F - (fluoromisonidazole) FMISO-PET and immunohistochemistry (IHC) as the standard of references.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Imaging hypoxia for head and neck cancer: current status, challenges, and prospects.
Huang W, Li N, Zhu S, Zhang Y, et al · · 2025 · PMID 40860130 · DOI 10.7150/thno.112781
Verify or expand the search:
- PubMed search for NCT06108089
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other University of Utah trials
Trials by the same sponsor.
- NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
- NCT07225426 — Personalizing Financial Incentives · NA · recruiting
- NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
- NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
- NCT04208984 — Diversion Device With Breath Control · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06108089 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Utah
- Last refreshed: 12 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06108089.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing